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Infused vincristine and adriamycin with high dose methylprednisolone
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Summary Forty-five patients with relapsed or refractory multiple myeloma received continuous infusions of
vincristine (0.4mg total dose daily for 4 days) and adriamycin (9mgm-2 daily for 4 days) with a high dose of
methylprednisolone (1 gm-2 i.v. or p.o. daily by 1 h infusion), the VAMP regimen. Sixteen (36%) responded,
with a median duration of remission of 11 months and median survival of 20 months. Major toxicities
encountered were infective and cardiovascular. Two smaller groups of myeloma patients were treated with
high dose methylprednisolone (HDMP) alone, or VAMP plus weekly low dose cyclophosphamide (Cyclo-
VAMP). HDMP produced short responses in 25% of patients with less toxicity than VAMP. Cyclo-VAMP
was used in a highly selected group of patients who had previously responded to high dose melphalan. It was
well tolerated and produced responses in 61% of this group.
For the last 30 years the alkylating agents melphalan and
cyclophosphamide, alone or in various combinations have
formed the basis of treatment for multiple myeloma. The
management of patients who are, or who have become
refractory to these agents has been unsatisfactory. Only 25%
of relapsed patients will respond to alkylating agent contain-
ing combinations, and such remissions are short (Bonnet et al.,
1982; Kyle et al., 1982). In 1983 Alexanian et al. reported
responses in 47% of patients with refractory myeloma
treated with a combination of vincristine (1.5mgm 2 given
day 1, repeated day 25), adriamycin (35 mgm-2 i.v. day I
repeated day 25) and high dose prednisone (45 mgm-2 daily
for 5 days repeated every 8 days), the VAP regimen.
Subsequently, the same group studied the effect of con-
tinuously infused vincristine (0.4mg total dose daily for 4
days) and adriamycin (9mgm-2 daily for 4 days) with even
higher dose corticocosteroids given as dexamethasone (40mg
total dose for 4 days repeated day 1, 9 and 17, VAD)
(Barlogie et al., 1984; Alexanian et al., 1986). Sixty-five
percent of patients relapsing after previous chemotherapy
and 32% of patients refractory to first-line treatment res-
ponded to VAD. High dose dexamethasone alone was found
to be as effective as the combination in refractory patients.
They concluded that patients with relapsed or resistant
myeloma should be offered a trial of the VAD regimen.
Table I Patient characteristics
Number of patients
Age distribution: <40
40-49
50-59
60-70
>70
We have explored the use of vincristine and adriamycin by
infusion together with high doses of methylprednisolone
(VAMP) as an alternative regimen for relapsed or resistant
myeloma patients. We used methylprednisolone because of
previous experience with this drug for refractory myeloma
and the severe toxicity observed in 8 patients treated with
VAD regimen (3 severe septic episodes, 4 cardiovascular
episodes including 2 deaths and myopathy in all patients).
We have also used high dose methylprednisolone in the treat-
ment of other lymphoid and haematological malignancies
and for graft versus host disease after allotransplantation.
Short, high dose pulses of methylprednisolone seemed to be
associated with less toxicity than dexamethasone used in the
VAD regimen. In this paper we report the efficacy and
toxicity of VAMP and of high dose methylprednisolone in
previously treated myeloma patients. In patients who had
relapsed after good responses to high dose melphalan (Selby
et al., 1987) we added cyclophosphamide to VAMP (Cyclo-
VAMP) seeking to increase the efficacy of the regimen in
this group who were selected to have tumours sensitive to
alkylating agents. The results of this treatment are also
described.
Materials and methods
Patients
Between January 1985 and September 1987, 45 patients
Cyclo- (Table I) aged 34-73 were treated with the VAMP regimen
VAMP VAMP HDMP (Table II). Eighteen other patients aged 27-58, received
45 18 16 Cyclo-VAMP (Table II). Sixteen patients aged 38-79 who
were considered unsuitable for VAMP because of age or
2 2 0 poor performance status or who refused further cytotoxic
17 9 4 chemotherapy were treated with high dose methyl-
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1 Table II Chemotherapy regimens
Sex:
Myeloma subtype:
Bence-Jones
Non-secretory
Light chain:
Stage:
Plasma cell leukaemia
Male/Female 30/15
IgG
IgA
IgD
(BJ)
(NS)
27
4
1
11
2
K 27
L 16
IA
IIA
IIIA
IIIB
(PCL)
36
6
1
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I. VAMP
Vincristine C
Adriamycin 9
Methylprednisolone I
Repeat every 21 days
0.4 mgday:1I for 4 days by
9m2day-1 J continuous infusion
1.0 gmm2day- 1 (max. 1.5g)
i.v./p.o. for 5 days
9 10 II. Cyclo-VAMP
9 6 VAMP as above plus
I _ Cyclophosphamide 500mg i.v. days 1, 8, 15
1 _ (Day 8 and 15 cyclophosphamide given
14 14 if total neutrophil count > 1.0 x 109 1- 1)
2 2 III. HDMP
- - Methylprenisolone 1.Ogm-2 (max. 1.5g)
p.o./i.v. daily for 5 days
Repeat every 21 days
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prednisolone (HDMP). Patients in all 3 groups had
advanced, progressive myeloma. None of the patients had
stable disease at the time of treatment with VAMP or the
other regimens. All patients receiving VAMP and Cyclo-
VAMP had received prior chemotherapy and had relapsed
following this or had failed to respond. Two patients
receiving HDMP had had no previous treatment. Patient
characteristics and details of previous chemotherapy are
given in Tables I and III.
Assessment
All patients were investigated with full blood count, differen-
tial white cell count and ESR, serum biochemistry, including
urea and electrolytes, creatinine, calcium and glucose, serum
immunoglobulins, serum and urine protein electrophoresis,
EDTA clearance to estimate glomerular filtration rate, bone
marrow aspirate and trephine and full radiological skeletal
survey. Staging was according to the Salmon and Durie
classification (Durie & Salmon, 1975). Full blood counts,
serum biochemistry, serum and urine protein electrophoresis
and serum immunoglobulins were repeated with every course
of treatment and thereafter at every follow-up out-patient
visit (i.e. 1-3 monthly). Bone marrow examinations were
repeated at the end of treatment and thereafter at 3 to 6
monthly intervals or if a change in the status of disease was
suspected.
Treatment
The chemotherapy regimens are given in Table III. In all
cases vincristine and adriamycin were mixed together and
infused continuously for 4 days through an infusion pump
(Acta pump, Pharmacia Ltd). A central venous catheter
(subclavian line, Hickman line or Portacath) was always
used for infusions because of the risk of tissue necrosis
should the mixture extravasate from a peripheral vein.
Methylprednisolone (Solu Medrone, Upjohn Ltd.) was
infused in 100ml of 5% dextrose over 30min; or was taken
orally, in which case the intravenous preparation was dis-
solved in water. The resulting solution was usually mixed
with fruit juice or cordial to disguise the bitter taste.
Pharmokinetic studies show that methylprenisolone is 100%
bioavailable when given orally (unpublished data). Treat-
ment was repeated every 21 days provided that the total
peripheral neutrophil count at the start of treatment was
greater than 2.0 x 1091-1 and platelets greater than
1OOxlO91-1. In the Cyclo-VAMP regimen, day 8 and 15
cyclophosphamide was given provided that the neutrophil
count was 1.0 x 109 1-1 or greater.
All patients received prophylactic oral anti-fungals (nysta-
tin suspension and amphoteracin lozenges) and cimetidine
800mgday-1 or ranitidine 300mgday-' for at least the first
10 days of each treatment course. Allopurinol 300mgday-1
was given concurrently with the first two courses. Patients
who became significantly hyperglycaemic also received gli-
benclamide 5-20mgday-1 with subsequent treatments. Pro-
phylactic anti-bacterial chemotherapy was not given.
Criteria of response
Response to these treatments was defined by the same
criteria as we used to describe response to HDM (Selby et
al., 1987), i.e.
Complete remission (CR) Normal bone marrow morpho-
logy (<5% plasma cells with no abnormal forms seen) and
unmeasurable serum and urine myeloma protein by electro-
phoresis on at least 2 consecutive occasions one month
apart.
Partial remission (PR) Fifty percent or greater reduction in
serum and urine myeloma protein and improvement in all
other clinical features sustained for greater than one month.
Evidence of bone healing was not required as a criterion
of response.
Early death Death prior to completing 2 courses of treat-
ment. Such patients are considered as non-responders and
have not been excluded from the number of patients con-
sidered assessable for response.
Results
Antitumour effect
(i) VAMP Of the 45 patients treated with VAMP, 2 died
from treatment toxicity prior to completing 2 courses and
are considered as non-responders. Sixteen patients (36%)
achieved a response to VAMP, one of which was complete
(Table IV). The Kaplan-Meier curve for duration of
remission is shown in Figure 1. Seven of those responding to
VAMP were treated with high dose intensive chemotherapy
while in remission as a consolidation, and these 7 patients
are censored from analysis at the time of their consolidation
treatment. The median duration of remission is 11 months.
Three patients had remissions of over one year after VAMP
treatment with consolidation and 2 of these remain in
remission at 28 and 29 months from the start of treatment.
Actuarial median duration of survival from VAMP treat-
ment is 20 months (Figure 2).
Table III Previous treatment
Cyclo-
VAMP VAMP HDMP
Number of patients: 45 18 16
Number of previous treatments:
Untreated NA NA 2
1 25 16 7
2 16 1 4
>3 4 1 3
Previous low dose alkylating agents:
Number treated 32 3 8
Number responding 6 1 0
Previous high dose melphalan (HDM):
Number treated 15 16 8
Number responding 5 16 4
Previous adriamycin:
Number treated 6 0 4
Number responding 2 - 0
Previous HDMP:
Number treated 9 0 0
Number responding 2 - -
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Table IV Response to treatment
VAMP Cyclo-VAMP HDMP
Number of patients: 45 18 16
Number of treatment courses:
Range 1-7 2-7 1-8
Median 4 4 4
Number of responders:
Complete remission (CR) 1 2 0
Partial remission (PR) 15 9 4
No change (NC) 21 6 12
Progressive disease (PD) 6 1 0
Early death 2 0 0
Response rate:
CR+PR All pts 16/45 (36%) 11/18 (61%) 4/16 (25%)
Relapsed pts 9/20 (45%) 10/16 (63%) 1/4 (25%)
Number treated Resistant pts 7/25 (28%) 1/2 (50%) 1/10 (10%)
Remission duration (mo.): range 3-29+a 2+-8b 2-6
median 11 4 4
Median survival:
From date of treatment (mo.) 20 not reached 10
'7/16 responding patients received further treatment while in remission; b9/11 responding patients
received further treatment while in remission.
Responses to VAMP were seen in patients who had
proven to be resistant to other forms of chemotherapy.
Thus, 6/26 who had failed treatment with conventional dose
alkylating agents responded to VAMP, as did 3/4 patients
resistant to a previous adriamycin-contaimnng combination,
2/6 resistant to HDM and 1/4 resistant to high dose
methylprednisolone. Table IV also categorises patients into
relapsed or resistant groups depending upon the response to
previous chemotherapy. Any patient who had responded to
previous chemotherapy is categorised as relapsed, while the
resistant group had never shown evidence of drug-sensitive
disease and had never entered a plateau phase. Response
rates are higher for the relapsed group (45% vs. 28%) but
this difference does not reach statistical significance.
Five patients were treated with VAMP who had previously
received VAMP or a similar combination (2 VAMP, 2 VAD,
1 Cyclo-VAMP). These patients are not described in the
above analysis. None of them responded to retreatment with
VAMP.
(ii) Cyclo-VAMP Eleven (61%) of those treated with
Cyclo-VAMP responded and 2 of these responses were
complete. The majority of this group (16/18) had previously
responded to HDM, and elective consolidation treatment
with HDM was planned for those responding to Cyclo-
VAMP. Nine of 11 responders to Cyclo-VAMP received
consolidation HDM so that remission duration for Cyclo-
VAMP cannot be described. Eighty percent of patients
receiving Cyclo-VAMP are alive (Figure 3)
period of 18 months.
with a follow-up
(iii) HDMP Four patients (25%) responded to treatment
with HDMP. These remissions were short (2 to 6 months).
Median survival from treatment with HDMP was 10
months.
Both the previously untreated patients responded to
HDMP. The remaining 2 responders had both been pre-
viously treated with alkylating agents.
Toxicity
A detailed prospective record of toxicity was recorded by
one of us (CV) at each treatment. Infection and cardio-
vascular problems were the major toxicities encountered.
Infection complicated particularly the VAMP and Cyclo-
VAMP groups (Table V) while cardiovascular toxicity was
seen in those receiving VAMP and HDMP.
(i) VAMP (a) Gastrointestinal: Mild nausea occurred in 5 (11%)
of those treated with VAMP, while 4 (9%) experienced more severe
nausea and vomiting (WHO Grade 2 or 3). Two patients had
episodes of mild colicky abdominal pain, while one patient had 2
episodes of moderately severe gastrointestinal haemorrhage. Investi-
gation revealed no definite source of bleeding in this patient,
although clinically it appeared that this was lower GI tract
haemorrhage.
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Table V Infective toxicity
Cyclo-
VAMP VAMP HDMP
Number treated 45 18 16
Patients developing infection
requiring treatment 28 (62%) 10 (55%) 4 (25%)
Patients developing multiple
infections 12 (27%) 3 (17%) 0
Episodes of severe infection
(WHO Grades 3 and 4) 14 4 0
Infective deaths 1 (2%) 0 0
(b) Alopecia: Thirty-seven (82%) patients receiving VAMP com-
plained of hair loss and this was severe enough to require a wig
(WHO Grade 2 or greater) in 21 (46%).
(c) Neurological: Mild, transient parasthesiae were reported by 11
(24%) patients and one developed more severe parasthesiae asso-
ciated with slight motor weakness. No cases of myopathy were
noted.
(d) Hyperglycaemia: A random blood glucose of greater than
11.0mmoll-1 was a new finding seen in 14 (31%) of those treated
with VAMP. Only in 5 cases, however, was the hyperglycaemia
severe enough to require treatment with oral hypoglycaemic agents.
(e) Central/Hickman Line: Seven patients (16%) suffered compli-
cations related to their central venous catheter. Three patients
developed catheter-associated infections, septicaemia in 2 and a
severe exit-site cellulitis in the third. Pneumothorax following place-
ment of a subclavian line occurred in 3 cases, although none of these
required intercostal tube drainage. In one patient early removal of
the Hickman line was required because of subclavian vein
obstruction.
(f) Haematological: Significant anaemia (lowest recorded haemo-
globin of less than 9.5gdl-1 recorded while on treatment) occurred
in 25 (66%) VAMP patients. The white cell count fell below
2.0 x 1091-1 in only 13 (29%), and a platelet count of under
50 x I0 1- at any time on treatment was seen in only 6 (14%).
(g) Infective: Twenty-eight (62%) of patients had at least one
episode of infection requiring antibiotics while on VAMP, and 12
(27%) had multiple infective episodes. Ten patients suffered 14
episodes of severe or life-threatening infection (WHO Grade 3 or 4)
and there was one septicaemic death. Blood cultures were positive in
7 of these patients; the isolated organisms were: Escherisa coli (2
cases), Staphylococcus aureus (2 cases including one septic arthritis),
Klebsiella aerogenes, Streptococcus faecium and S. epidermis (one
case each). Four other seriously infected patients had positive urine
cultures although blood cultures were negative. E. coli and a
Klebsiella species bacteria each occurred in 2 of these patients. Two
further patients suffered shingles or severe Herpes simplex infections
while on treatment. There was no apparent relationship between age
and the development of infective complications.
(h) Cardiovascular: Five patients experienced severe cardiovascular
events during treatment, and these complications were fatal in 3
cases. Two problems predominated, and were occasionally com-
bined: (i) Congestive heart failure, which was sudden in onset, not
preceded by measurable weight gain and refractory to treatment,
and (ii) symptoms of myocardial ischaemia which were again
difficult to control and progressed to myocardial infarction and
death in 2 cases. Cardiovascular problems tended to occur during
the five days of receiving HDMP or within a few days of completing
treatment. All but one of these patients had either a prior history of
heart disease or were aged 70 or over. One of the cardiovascular
deaths, however, occurred in a patient with neither of these apparent
risk factors. One other patient experienced repeated syncopal epi-
sodes following each treatment course, possibly related to cortico-
steroid withdrawal.
(ii) Cyclo-VAMP (a) Gastrointestinal: Six patients (33%) reported
mild nausea. None experienced vomiting or other GI symptoms.
(b) Alopecia: Hair loss was more marked than with VAMP. All
patients experienced some hair loss and this was moderate or severe
(WHO Grade 2 or greater) in 15 (83%).
(c) Neurological: Nine (50%) experienced mild, transient parasthe-
siae. One patient without a prior history of epilepsy suffered
repeated grand mal convulsions 3 days after starting the first course
of Cyclo-VAMP. Investigation with CT scans and lumbar puncture
revealed no cause for this fitting and it is therefore possibly related
to the chemotherapy. No cases of myopathy were noted.
(d) HIvperglvcaemia: Four patients (22%) developed a blood
glucose of > 11.0mmolI I while on treatment, one of these required
treatment.
(e) Central/Hickman Line: There was one case of septicaemia
related to a Hickman line, and two patients developed pneumo-
thoraces from insertion of a subclavian line, one of which required
intercostal tube drainage.
(f) Haematological: Severe anaemia (Hb <9.5gdl-1) occurred in
6 (33%) of patients while on Cyclo-VAMP. Severe neutropenia
(WCC <2.0 x 109) was seen in 5 (27%) while one patient (6%) had
a platelet count of less than 50 x 1091. Cyclophosphamide was
omitted on at least one occasion in 10 patients and a total of 23
doses were omitted. Eight courses were delayed by one week.
(g) Infective: Infection was a major cause of morbidity as in the
VAMP group. Ten patients (55%) required treatment for infection,
and 3 (17%) experienced multiple infections. Four patients suffered
5 episodes of severe or life-threatening infections, although in this
group there were no infective deaths. Three septicaemic patients had
positive blood cultures, E. coli was isolated twice and Aeromonas
hydrophilia once.
(h) Cardiovascular: There was no cardiovascular toxicity recorded
in this group of patients.
(iii) HDMP (a) Gastrointestinal: One patient complained of dys-
pepsia despite receiving prophylactic cimetidine, this was relieved by
antacids; and mild nausea occurred in one other patient.
(b) Hyperglycaemia: Nine patients (56%) developed hyper-
glycaemia. This required treatment in 3.
(c) Haematological: Severe anaemia (Hb <95gdl-1) occurred in
3 patients (19%) and severe thrombocytopenia (platelet count
<50 x 1091-1) in 1 (6%). This is likely to reflect disease activity
rather than treatment toxicity as may some of the haematological
toxicity ascribed to VAMP and Cyclo-VAMP.
(d) Infective: Four patients (25%) required treatment for infec-
tion, none of these, however, were severe, there were no cases of
multiple infection or infective deaths. One patient developed shingles
on HDMP.
(e) Cardiovascular: Severe angina complicated treatment in 2
patients, but there were no deaths attributable to cardiovascular
toxicity.
(f) Other: One patient complained of lethargy and one of myalgia
on completing their course of steroids. These were mild and did not
prevent further treatment. No cases of myopathy were noted.
No patients developed neurological symptoms or alopecia, and
this group did not require central venous access.
Discussion
In this group of heavily pretreated patients with multiple
myeloma, we obtained useful remissions in 36% of 45
patients using VAMP chemotherapy. As VAMP is derived
from the VAD regimen (Barlogie et al., 1984; Alexanian et
al., 1986) it is interesting to compare our results with those
obtained with VAD despite the difficulties inherent in such
comparisons. In addition to Alexanian's group, Anderson et
al. (1987) have recently published their experience with the
VAD regimen in 22 patients with relapsed (7) or resistant
(15) multiple myeloma. In Table VI the response rates are
compared for the three studies. Our response rate to VAMP
(36%) is lower than that obtained with VAD both by
Alexanian's group (46%) and Anderson et al. (50%). These
differences are not statistically significant. Alexanian et al.
(1986) found that VAD was significantly more effective in
those patients with previously demonstrated chemosensitive
disease (relapsed patients) than in those with primary drug
Table VI Comparative responses VAMP vs VAD
Responses (%)
Previously Previously
All responsive unresponsive
Regimen pretreated (relapsed) (resistant)
VAMP 10/45 (36) 9/20 (45) 7/25 (28)
VAD
(Alexanian et al.) 18/39 (46) 11/17 (65) 7/22 (32)
VAD
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resistance (resistant patients). The results with VAMP are
similar (45% vs. 28%) but not significant statistically.
Anderson et al. (1987) did not show an increased responsive-
ness of relapsed over resistant patients to VAD (43% vs.
53%) so the three studies combined suggest only a modest
advantage to the relapsed patients.
Most of the published data on VAD used for previously
treated patients suggests that remissions obtained have been
short. Alexanian et al. (1986) obtained a median duration of
remission of 9 months and survival was 14 months, although
responders survived a median of 22 months. The remissions
achieved by Anderson et al. (1987) lasted a median of 6
months and median survival was 9 months. The 11 month
median duration of remission we have obtained with VAMP
compares favourably with these results, particularly as 7 of
the 16 responders were censored from analysis at the time of
high dose melphalan. Remissions of over 2 years were seen
in 2 patients who did not receive consolidation. Median
survival from treatment with VAMP is 20 months which also
compares favourably with VAD, although consolidation with
HDM may have biased this result in favour of longer
survival.
VAMP chemotherapy is associated with considerable mor-
bidity and some mortality. There was little symptomatic
upset and alopecia was usually mild or moderate. However,
infective and cardiovascular toxicity was severe in some
cases. Of 6 treatment-related deaths seen with VAMP, 5
were cardiovascular from intractable congestive heart failure
or myocardial infarction. Cardiovascular events were as
common with high dose methylprednisolone used alone (2
out of 16 patients) suggesting that this toxicity is due to the
high dose of corticosteroid. Cardiovascular morbidity is,
however, at least partially predictable, and we no longer use
this dose of methylprednisolone in patients with a history of
heart disease or who are over 70 years of age.
Infective toxicity was a major concern. Two thirds of our
patients required antibiotic treatment for infection, while
20% suffered potentially life-threatening infections not asso-
ciated with neutropenia. Although there was only one septi-
caemic death over the period of this analysis, subsequently,
we have seen 3 septic deaths in patients with previously
untreated myeloma while receiving this treatment. Anderson
et al. (1987) and Barlogie et al. (1984) also found infection
to be a major problem in patients receiving VAD, and also
found it to be unrelated to neutropenia. Barlogie et al. have
attributed this at least partially to the high dose steroids. In
our patients treated with HDMP alone, infection occurred
less often than in those receiving VAMP and Cyclo-VAMP,
and there were no episodes of severe infection. Many of
these patients are prone to infection because of the immuno-
paresis and possible bone marrow failure associated with
their disease. The need for a central venous catheter adds an
important source of infection, 3 of the 14 episodes of severe
sepsis were catheter-associated.
The most commonly identified organisms responsible for
the severe infections were E. coli, Staphylococcus aureus and
bacteria of the Klebsiella genus; although a number of other
gram positive and gram negative organisms were isolated less
frequently. Anderson et al. (1987) gave prophylactic cotri-
moxazole concurrently with VAD, but still found infection
to be a major problem. No simple antibiotic regimen could
be used prophylactically given the range of organisms iso-
lated both by us and by Anderson's group. Patients receiving
these treatments require very careful surveillance for sepsis
and should be vigorously instructed to report at the first sign
of possible infection.
We had previously noted myopathy - mainly of proximal
leg muscles - in our patients receiving VAD. Thi's was not
seen with VAMP or related regimens, presumably because of
the shorter duration of steroid administration.
As the patients treated with Cyclo-VAMP were selected as
having chemo-sensitive disease, it is not possible to make
any useful comparison of the efficacy of this regimen with
VAMP. The overall response rate is high at 61%, and we
have demonstrated that at least in this group of relatively
young patients the addition of cyclophosphamide was not
associated with increased toxicity. It may therefore be useful
to consider using the Cyclo-VAMP regimen particularly for
younger patients who have relapsed following successful
treatment with an alkylating agent.
We do not feel that high dose methylprednisolone alone
has a major role in the treatment of myeloma. Responses are
infrequent (25%) and short. HDMP may provide good
palliation in patients who have failed or who are unsuitable
for other treatments. HDMP may prove useful in patients
presenting with bone marrow failure.
In conclusion, we have found the VAMP regimen to be
effective in the treatment of both relapsed and refractory
myeloma and it may be considered in patients with primary
drug resistance as well as those with relapsed disease. A
small number of long remissions were obtained with this
treatment. Infective and cardiovascular complications may
be severe. We are now using it to induce remission in
previously untreated patients as a preparation for high dose
melphalan with autologous bone marrow transplantation.
Twenty-seven patients are evaluable for response to VAMP
and responses have occurred in 19 (70%) including two
complete remissions. VAMP and related regimens are clearly
powerful additions to the treatment options for new and
previously treated patients.
As Clinical Editor, British Journal of Cancer, Dr Selby wishes it to
be known that this manuscript was evaluated for publication
independently of him.-Ed-in-C.
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